Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Gastrointestinal 2Breast 2Gynecologic 1Genitourinary 1

Conditions

Pancreatic Neoplasms 170Neoplasms 66Carcinoma, Non-Small-Cell Lung 49Neoplasm Metastasis 37Unspecified Adult Solid Tumor, Protocol Specific 25Ovarian Neoplasms 21Breast Neoplasms 21Urinary Bladder Neoplasms 20Cholangiocarcinoma 20Lymphoma 19Colorectal Neoplasms 18Lymphoma, Non-Hodgkin 17Lung Neoplasms 17Sarcoma 16Hodgkin Disease 14Fallopian Tube Neoplasms 14Biliary Tract Neoplasms 13Lymphoma, Large B-Cell, Diffuse 12Gallbladder Neoplasms 11Colonic Neoplasms 11Carcinoma, Ovarian Epithelial 11Stomach Neoplasms 10Recurrence 10Solid Tumors 9Bile Duct Neoplasms 8Adenocarcinoma 8Triple Negative Breast Neoplasms 7Small Cell Lung Carcinoma 7Rectal Neoplasms 7Melanoma 7

Interventions

Cisplatin 9pembrolizumab 7Irinotecan 7Radiotherapy 6Fluorouracil 6Docetaxel 5spartalizumab 4Oxaliplatin 4130-nm albumin-bound paclitaxel 4Nivolumab 3Carboplatin 3toripalimab 2tislelizumab 2elgemtumab 2durvalumab 2Radiation 2Paclitaxel 2Leucovorin 2Gemcitabine 2Drug Therapy 2vandetanib 1tremelimumab 1ribociclib 1palbociclib 1obinutuzumab 1nedaplatin 1nazartinib 1naptumomab estafenatox 1liposomal doxorubicin 1dalpiciclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Esophageal Squamous Cell Carcinoma × Gemcitabine × Clear all
NCT04060342 2022-08-18

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Gossamer Bio Inc.

Phase 1 Terminated
61 enrolled
BreastGastrointestinalGenitourinaryHead & NeckThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

AstraZeneca

Phase 1 Completed
32 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡